CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
memantine +1 moredrug
Likely dose
memantine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00344682
NCT00344682Phase 4Completed
CompareCT.gov

A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders

University of Massachusetts, Worcester·interventional·Posted Jun 27, 2006·Updated Jul 11, 2018

In Brief

A Phase 4 clinical trial evaluating memantine and Placebo for Depressive Disorder. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 20.0 years ago

Interventions

memantinedrug

memantine 5mg - 20mg PO daily

Placebodrug

5mg - 20mg PO daily over 8 weeks